GlaxoSmithKline PLC — Director's Dealing 2018

Feb 20, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4137F

GlaxoSmithKline PLC

20 February 2018

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	12,482 (Deferred)
	£0.0000	8,614 (Matching)
d)	Aggregated information
Aggregated volume Price	21,096 £0.0000
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£13.1563	5,868 (Deferred)
	£13.1563	4,050 (Matching)
d)	Aggregated information
Aggregated volume Price	9,918 £13.1563
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Connor
b)	Position/status	President, Global Manufacturing & Supply
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	9,142 (Deferred)
	£0.0000	6,308 (Matching)
d)	Aggregated information
Aggregated volume Price	15,450 £0.0000
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Connor
b)	Position/status	President, Global Manufacturing & Supply
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£13.1028	4,384 (Deferred)
	£13.1200	3,026 (Matching)
d)	Aggregated information
Aggregated volume Price	7,410 £13.1114
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	17,435 (Deferred)
	£0.0000	12,030 (Matching)
d)	Aggregated information
Aggregated volume Price	29,465 £0.0000
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£13.1236	8,360 (Deferred)
	£13.1230	5,768 (Matching)
d)	Aggregated information
Aggregated volume Price	14,128 £13.1233
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics and Compliance
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	6,402 (Deferred)
	£0.0000	4,418 (Matching)
d)	Aggregated information
Aggregated volume Price	10,820 £0.0000
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics and Compliance
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£13.1068	3,070 (Deferred)
	£13.1118	2,120 (Matching)
d)	Aggregated information
Aggregated volume Price	5,190 £13.1093
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	10,258 (Deferred)
	£0.0000	7,078 (Matching)
d)	Aggregated information
Aggregated volume Price	17,336 £0.0000
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£13.1800	4,822 (Deferred)
	£13.1800	3,328 (Matching)
d)	Aggregated information
Aggregated volume Price	8,150 £13.1800
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	13,805 (Deferred)
	£0.0000	9,525 (Matching)
d)	Aggregated information
Aggregated volume Price	23,330 £0.0000
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£13.1180	6,489 (Deferred)
	£13.1180	4,478 (Matching)
d)	Aggregated information
Aggregated volume Price	10,967 £13.1180
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	4,689 (Deferred)
	£0.0000	3,235 (Matching)
d)	Aggregated information
Aggregated volume Price	7,924 £0.0000
e)	Date of the transaction	2018-02-19
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£13.1240	2,204 (Deferred)
	£13.1240	1,521 (Matching)
d)	Aggregated information
Aggregated volume Price	3,725 £13.1240
e)	Date of the transaction	2018-02-19
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr P Vallance
b)	Position/status	Outgoing President, R&D
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	20,322 (Deferred)
	£0.0000	14,022 (Matching)
d)	Aggregated information
Aggregated volume Price	34,344 £0.0000
e)	Date of the transaction	2018-02-19
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr P Vallance
b)	Position/status	Outgoing President, R&D
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares following the exercise of options on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£13.1760	20,322 (Deferred)
	£13.1760	14,022 (Matching)
d)	Aggregated information
Aggregated volume Price	34,344 £13.1180
e)	Date of the transaction	2018-02-19
f)	Place of the transaction	London Stock Exchange (XLON)

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHXBLFLVLFFBBL